-
A New Hope for HER2-Positive Biliary Tract Cancer: FDA Approves Ziihera
NASDAQ: $JAZZ A Major Milestone in Oncology The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Ziihera (zanidatamab-hrii), marking a significant advancement for patients battling a specific, challenging form of cancer. This targeted therapy is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive biliary tract cancer (BTC).…
-
Compass Therapeutics (CMPX) enters the second half of 2026 in a strong financial position
NASDAQ: $CMPX Compass Therapeutics enters the second half of 2026 in a strong financial position, though its stock has recently experienced significant volatility following the long-awaited data readout for its lead program. Cash Runway As of the most recent financial updates in early 2026, Compass Therapeutics is exceptionally well-capitalized for a clinical-stage biotech: 2026 Pipeline…